Boehringer Ingelheim and Epizyme enter into global collaboration to develop novel epigenetic oncology therapies
Client(s) Boehringer Ingelheim GmbH
Jones Day represents Boehringer Ingelheim GmbH and Epizyme, Inc. in the establishment of a global patent portfolio related to small molecules to target enzymes within the helicase and histone acetyltransferase ("HAT") families.